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Background-—Extended-duration betrixaban showed a significant reduction in venous thromboembolism in the APEX trial (Acute
Medically Ill VTE Prevention With Extended Duration Betrixaban Study). Given the variable clinical impact of different efficacy and
safety events, one approach to assess net clinical outcomes is to include only those events that are either fatal or cause
irreversible harm.
Methods and Results-—This was a post hoc analysis of the APEX trial—a multicenter, double-blind, randomized controlled trial
comparing extended-duration betrixaban versus standard-of-care enoxaparin. A composite of all fatal or irreversible safety (fatal
bleeding or intracranial hemorrhage) and efficacy events (cardiopulmonary death, myocardial infarction, pulmonary embolism, and
ischemic stroke) was evaluated in a time-to-first event analysis. In patients with positive D-dimer results, betrixaban reduced fatal
or irreversible events at 35 to 42 days (4.80% versus 3.54%; hazard ratio, 0.73; absolute risk reduction, 1.26%; number needed to
treat, 79 [P=0.033]) and at study end at 77 days (6.27% versus 4.36%; hazard ratio, 0.70; absolute risk reduction, 1.91%; number
needed to treat, 52 [P=0.005]) versus enoxaparin. In all patients, betrixaban reduced fatal or irreversible events at 35 to 42 days
(4.08% versus 2.90%; hazard ratio, 0.71; absolute risk reduction, 1.18%; number needed to treat, 86 [P=0.006]) and 77 days (5.17%
versus 3.64%; hazard ratio, 0.70; absolute risk reduction, 1.53%; number needed to treat, 65 [P=0.002]).
Conclusions-—Among hospitalized medically ill patients, extended-duration betrixaban demonstrated an 30% reduction in fatal or
irreversible ischemic or bleeding events compared with standard-duration enoxaparin. A total of 65 patients would require
treatment with betrixaban to prevent 1 fatal or irreversible event versus enoxaparin.
Clinical Trial Registration-—URL: http://www.ClinicalTrials.gov. Unique identifier: NCT01583218. ( J Am Heart Assoc. 2017;6:
e006015. DOI: 10.1161/JAHA.117.006015.)
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T herapeutic interventions are associated with bothefficacy benefits and safety hazards. The net clinical
outcome of an intervention can be assessed by combining
measures of efficacy and safety. Some events may be
transient and reversible and result in no permanent harm,
which makes them challenging to weigh against each other.
One way to ensure that the clinical impact of the efficacy and
safety events that are being compared is similar is to include
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only those events that are either fatal or result in irreversible
cell death or harm to the patient. The present study is a post
hoc analysis of the APEX trial (Acute Medically Ill VTE
Prevention With Extended Duration Betrixaban Study), which
evaluates net clinical outcomes by comparing a composite of
fatal or irreversible efficacy and safety events in patients
treated with extended-duration betrixaban versus standard
dosing enoxaparin for venous thromboembolism prevention
among acute medically ill hospitalized patients. This article
expands on the primary results of APEX, which assessed
efficacy and safety end points independently. Additionally, the
end point evaluated in this study includes only symptomatic
events and therefore could be assessed in the modified
intent-to-treat population, as opposed to the primary efficacy
outcome population, which was used for the primary results.
Methods
Study Design and Population
APEX was a randomized, double-blind, double-dummy, active-
controlled, multinational phase 3 clinical trial. The trial design
and main results have been previously published.1,2 In brief,
acutely medically ill men and women, 40 years or older, with
reduced mobility and increased risk for venous thromboem-
bolism hospitalized for either acute heart failure, respiratory
failure, infectious disease, rheumatic disease, or ischemic
stroke were eligible for enrollment. Major exclusion criteria
were active bleeding or a high risk of bleeding, severe renal
insufficiency with creatinine clearance <15 mL/min, or any
condition requiring prolonged anticoagulation or antiplatelet
therapy.
Patients were randomly assigned in a 1:1 ratio to receive
either standard-duration subcutaneous enoxaparin 40 mg
once daily for 104 days plus oral betrixaban placebo once
daily for 35 to 42 days or subcutaneous enoxaparin placebo
once daily for 104 days plus active extended-duration oral
betrixaban (loading dose of 160 mg for the first dose followed
by 80 mg once daily for 35–42 days). The dose of study drug
was adjusted to 40 mg among patients with renal insuffi-
ciency with creatinine clearance <30 mL/min (both enoxa-
parin and betrixaban doses were halved) and patients
receiving concomitant strong P-glycoprotein inhibitors (only
betrixaban dose was halved). Clinical outcomes were
assessed between day 35 and day 42 and again at an
additional 305 days after day 42. The modified intent-to-
treat cohort was used, which included all randomized patients
who had at least one dose of study drug. The primary and first
cohort tested (cohort 1) included patients who had positive
D-dimer results (≥2 times the upper limit of normal) by local
laboratory assessment. Cohort 2 included patients who had
positive D-dimer results or were 75 years and older. In
addition, end points were assessed in all randomized patients
(Figures S1 and S2). The study was approved by the local
institutional review committees, and all enrolled participants
provided informed consent.
End Points
All safety and efficacy end points were adjudicated by
members of a clinical events committee blinded to study
group assignment. In this post hoc analysis, the primary end
point was the composite of all fatal or irreversible ischemic
and bleeding events. This composite end point was previously
used in the clinical trial assessment of prasugrel.3,4 An
irreversible efficacy end point was defined as death from
ischemic cerebral or cardiopulmonary causes, including
ischemic stroke, fatal arrhythmias, heart failure, venous
thromboembolism, and sudden death from unknown causes,
as well as nonfatal events that resulted in necrosis of tissue
including nonfatal myocardial infarction (MI), nonfatal pul-
monary embolism (PE), and nonfatal ischemic stroke. An
irreversible safety end point was defined as fatal bleeding or
intracranial hemorrhage. Nonfatal PE was not included as an
outcome in sensitivity analysis because some patients with PE
do not have necrosis of lung tissue.
Statistical Analysis
In the analysis of the 80- and 40-mg dose cohorts, the actual
dose the patient was treated with was used.
All statistical analyses were programmed independently by
two statisticians using SAS version 9.4 (SAS Institute Inc).
Characteristics of the study population were evaluated using
descriptive statistics. Data were expressed as frequencies
and percentages for categorical variables, with denominators
including all patients with available data. A time-to-first event
survival analysis with right censorship was performed using a
Cox proportional hazards regression model, where event rates
were expressed as Kaplan–Meier estimates, and P values
Clinical Perspective
What Is New?
• Among hospitalized medically ill patients through 77 days of
follow-up, 1 fatal or irreversible event could be prevented by
treating 65 patients with extended-duration betrixaban
compared with standard-of-care enoxaparin.
What Are the Clinical Implications?
• Extended-duration thromboprophylaxis using an experimen-
tal oral factor Xa inhibitor may reduce the risk of fatal or
irreversible events among hospitalized medically ill patients.
DOI: 10.1161/JAHA.117.006015 Journal of the American Heart Association 2
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were reported using the log-rank test. Events were analyzed
through visit 3 or day 42 to reflect the primary analysis and
through end of study at day 77 as an exploratory assessment.
All events (efficacy or safety) were considered to have equal
statistical weight. A P<0.05 was considered statistically
significant.
Results
The baseline characteristics of the two cohorts were well
matched.2 The median time overall on enoxaparin/enoxaparin
placebo and betrixaban/betrixaban placebo was 9 (interquar-
tile range, 7–13) and 36 (interquartile range, 34–39) days,
respectively.
Table 1. Composite of Fatal and Irreversible Events
Outcome*
Through Visit 3 or Day 42 Through Day 77
Betrixaban Enoxaparin† Betrixaban Enoxaparin†
Cohort 1
Composite, No./total No. (%) 82/2314 (3.5) 111/2313 (4.8) 101/2314 (4.4) 145/2313 (6.3)
Ischemic events, No.
Ischemic cardiopulmonary death‡ 68 74 84 99
Nonfatal ischemic stroke 5 11 7 14
MI 11 12 12 18
Nonfatal pulmonary embolism 5 17 5 20
Bleed events, No.
Fatal bleed 0 1 0 1
Intracranial hemorrhage 0 3 0 4
Cohort 2
Composite, No./total No. (%) 105/3407 (3.1) 139/3391 (4.1) 133/3407 (3.9) 180/3391 (5.3)
Ischemic events, No.
Ischemic cardiopulmonary death 81 92 103 120
Nonfatal ischemic stroke 8 15 10 20
MI 14 15 15 22
Nonfatal pulmonary embolism 9 18 9 22
Bleed events, No.
Fatal bleed 1 1 1 1
Intracranial hemorrhage 1 5 1 6
All randomized patients
Composite, No./total No. (%) 109/3759 (2.9) 153/3754 (4.1) 137/3759 (3.6) 194/3754 (5.2)
Ischemic events, No.
Ischemic cardiopulmonary death 84 103 106 131
Nonfatal ischemic stroke 8 16 10 21
MI 14 17 15 24
Nonfatal pulmonary embolism 10 20 10 24
Bleed events, No.
Fatal bleed 1 1 1 1
Intracranial hemorrhage 1 5 1 6
*Data for safety outcomes were evaluated through visit 3 or day 42. The breakdown of events adds up to more than the composite events because the composite includes only the first
event the patient experienced. Modified intention-to-treat population for cohort 1 and cohort 2 analyses.
†Enoxaparin was administered for 104 days, followed by oral betrixaban placebo for 35 to 42 days.
‡Includes fatal pulmonary embolism/venous thromboembolism—confirmed, fatal pulmonary embolism/venous thromboembolism—possible, fatal pulmonary embolism/venous
thromboembolism—probable, arrhythmic event, heart failure, fatal ischemic stroke, fatal myocardial infarction (MI), and sudden death of unknown cause.
DOI: 10.1161/JAHA.117.006015 Journal of the American Heart Association 3
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Composite event rates were consistently lower in the
betrixaban arm across all cohorts, including and excluding
nonfatal PE (Tables 1 and 2). In cohort 1 (patients with
positive D-dimer results), there was a significant reduction in
fatal or irreversible events at both visit 3 (35–42 days) and
visit 4 (77 days) (Figure 1). Given the positive results
observed in cohort 1, cohort 2 (patients with positive D-dimer
results or age older than 75 years) was then evaluated, which
showed a similar reduction in events at visit 3 (3.1% versus
4.1%; hazard ratio [HR], 0.75 [95% CI, 0.58–0.96]; P=0.02)
and visit 4 (3.9% versus 5.3%; HR, 0.74 [95% CI, 0.59–0.92];
P=0.007) in favor of betrixaban over enoxaparin. Given the
significant results in cohort 2, cohort 3 (all randomized
patients) was therefore tested and also demonstrated a
significant reduction in fatal or irreversible events (Figure 2) in
favor of betrixaban over enoxaparin. The number needed to
treat to prevent 1 efficacy event was 65 when comparing
betrixaban versus enoxaparin in all randomized patients
through the end of the study. Betrixaban did not show higher
risk for safety events from the composite when compared
with enoxaparin, thus the number needed to harm could not
be calculated. In all analyses, the improvement in net clinical
Table 2. Composite of Fatal and Irreversible Events Excluding Nonfatal Pulmonary Embolism
Outcome*
Through Visit 3 or Day 42 Through Day 77
Betrixaban Enoxaparin† Betrixaban Enoxaparin†
Cohort 1
Composite, No./Total No. (%) 78/2314 (3.4) 96/2313 (4.2) 97/2314 (4.2) 130/2313 (5.6)
Ischemic events, No.
Ischemic cardiopulmonary death‡ 68 72 84 99
Nonfatal ischemic stroke 5 11 7 14
Nonfatal MI 11 12 12 18
Bleed events, No.
Fatal bleed 0 1 0 1
Intracranial hemorrhage 0 3 0 4
Cohort 2
Composite, No./Total No. (%) 98/3407 (2.9) 124/3391 (3.7) 126/3407 (3.7) 164/3391 (4.8)
Ischemic events, No.
Ischemic cardiopulmonary death 81 90 103 120
Nonfatal ischemic stroke 8 15 10 20
Nonfatal MI 14 15 15 22
Bleed events, No.
Fatal bleed 1 1 1 1
Intracranial hemorrhage 1 5 1 6
All randomized patients
Composite, No./Total No. (%) 101/3759 (2.7) 136/3754 (3.6) 129/3759 (3.4) 176/3754 (4.7)
Ischemic events, No.
Ischemic cardiopulmonary death 84 101 106 131
Nonfatal ischemic stroke 8 16 10 21
Nonfatal MI 14 17 15 24
Bleed events, No.
Fatal bleed 1 1 1 1
Intracranial hemorrhage 1 5 1 6
*Data for safety outcomes were evaluated through visit 3 or day 42 and day 77. The breakdown of events adds up to more than the composite events because the composite includes only
the first event the patient experienced. Modified intention-to-treat population for cohort 1 and cohort 2 analyses.
†Enoxaparin was administered for 104 days, followed by oral betrixaban placebo for 35 to 42 days.
‡Includes fatal pulmonary embolism/venous thromboembolism—confirmed, fatal pulmonary embolism/venous thromboembolism—possible, fatal pulmonary embolism/venous
thromboembolism—probable, arrhythmic event, heart failure, fatal ischemic stroke, fatal myocardial infarction (MI), and sudden death of unknown cause.
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outcomes began to emerge during the parenteral period of
therapy.
In a sensitivity analysis, which excluded nonfatal PE from
the composite end point, betrixaban administration was
associated with a similar reduction in the risk of the other
fatal or irreversible events, which reached statistical
significance at 77 days, end of study (Figures S3 and
S4). In addition, in a sensitivity analysis excluding nonfatal
Figure 1. Time to first fatal or irreversible event in cohort 1. *End of trial defined as final
follow-up visit (30+5 days after visit 3). Enoxaparin was administered for 104 days, followed
by oral betrixaban placebo for 35 to 42 days. ARR indicates absolute risk reduction; HR, hazard
ratio; NNT, number needed to treat.
Figure 2. Time to first fatal or irreversible event in the randomized population. *End of trial
defined as final follow-up visit (30+5 days after visit 3). Enoxaparin was administered for
104 days, followed by oral betrixaban placebo for 35 to 42 days. ARR indicates absolute risk
reduction; HR, hazard ratio; NNT, number needed to treat.
DOI: 10.1161/JAHA.117.006015 Journal of the American Heart Association 5
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PE and MI, there was a reduction of fatal or irreversible
events in all randomized patients comparing betrixaban
versus enoxaparin through visit 3, or day 42 (HR, 0.71; 95%
CI, 0.54–0.94 [P=0.016]) and through visit 4, or day 77
(HR, 0.72; 95% CI, 0.57–0.92 [P=0.008]). As a sensitivity
analysis, the data were analyzed using the Cochran-Mantel-
Haenszel test, which also yielded a significant event
reduction across all cohorts of patients and time windows
(Table S1). In addition, a sensitivity analysis that replaced
cardiopulmonary death with all-cause mortality showed no
significant benefit across all cohorts through visit 3 and the
end of the study (Table S2).
In a series of similar analyses limited to patients receiving
the full dose of betrixaban (80 mg), there was a consistent
reduction in fatal or irreversible events as compared with
enoxaparin (Table S3). Fatal or irreversible events were
significantly reduced in both cohort 1 and all randomized
patients (Figure 3 and Figure S5). In the smaller group of
patients treated with the adjusted dose of betrixaban (40 mg),
there was no significant reduction in events versus enoxaparin
(Table S4 and Figure S6).
Of the 6 patients in the enoxaparin arm who experienced
intracranial hemorrhages, 3 occurred while receiving enoxa-
parin and the remaining occurred while receiving either
betrixaban placebo or no drug at all. No patients had renal
insufficiency, and 5 of the 6 patients had creatinine
clearances ≥60, while one had a clearance 30 to <60.
There was a significant reduction in the incidence of the
traditional cardiovascular triple end point of cardiovascular
death, MI, and all-cause stroke with extended-duration
betrixaban versus standard duration enoxaparin in all ran-
domized patients through visit 3 and visit 4. There was a 27%
reduction in relative risk at visit 3 (2.29% versus 3.14%,
P=0.023) and 25% at visit 4 (2.98% versus 3.97%, P=0.002)
(Figure S7).
Discussion
Assessment of net clinical outcome, the combined impact of
efficacy and safety data, is a commonly requested evalua-
tion on the part of healthcare providers, payers, and
regulators. The decision to administer an agent is a binary
decision (either yes or no), and safety and efficacy in
making such a decision must both be considered simulta-
neously. In many analyses, reversible bleeding events with
no permanent sequelae are combined with intracranial
hemorrhage and fatal bleeding, which cause irreversible
harm. Some analyses rely on a time-to-first bleeding event
methodology. In such analyses, if the first event is minor, it
may obscure the clinical impact of a later event associated
with fatal or irreversible harm. As a relevant precedent, the
Food and Drug Administration approved prasugrel based on
its reduction of fatal and irreversible events related to either
ischemia end points for efficacy or bleeding for safety and
Figure 3. Time to first fatal or irreversible event in the randomized population—full dose (80 mg).
*End of trial defined as final follow-up visit (30+5 days after visit 3). Enoxaparin was administered
for 104 days, followed by oral betrixaban placebo for 35 to 42 days. ARR indicates absolute risk
reduction; HR, hazard ratio; NNT, number needed to treat.
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published their method to focus on fatal and irreversible
events.3 Based on this important precedent, we adopted a
similar approach. The present study assessed outcomes
during a relatively short period of 2 months. If similar risk
reductions were maintained over a longer duration of follow-
up, greater absolute risk reductions may have been
observed.
This post hoc analysis of APEX demonstrates that
extended-duration betrixaban is associated with a significant
reduction in fatal or irreversible events as compared with
standard-duration enoxaparin. The benefit begins to emerge
during the period of parenteral therapy and increases through
the period of active treatment at 35 to 42 days as well as the
entire duration of follow-up at 77 days. Based on the data
from all randomized patients, one would need to treat 65
patients with betrixaban to prevent 1 fatal or irreversible
event as compared with enoxaparin. In general, a number
needed to treat <100 is considered compelling in clinical
practice.
In a traditional net clinical outcomes analysis where
efficacy events (including reversible and nonfatal efficacy
events such as a positive compression ultrasound for
asymptomatic proximal venous thromboembolism) are com-
bined with major bleeding events (many of which are
reversible and nonfatal), there is also a benefit in favor of
betrixaban.2 Because major bleeding was not increased with
betrixaban, the net benefit associated with the drug is
predominantly driven by its improved efficacy. However, a
numeric but not significant excess of intracranial hemor-
rhages in the enoxaparin strategy helped drive the net clinical
outcome in favor of betrixaban.
There was a significant reduction in fatal or irreversible
events in cohort 1. The full dose of betrixaban (80 mg) was
associated with a reduction in fatal or irreversible events,
whereas the adjusted dose (40 mg) was not. Furthermore, in
patients treated with the full 80-mg dose in cohort 1, there
was a robust 2.3% absolute risk reduction (P=0.002),
indicating that only 43 patients with positive D-dimer results
in cohort 1 would need to be treated with full-dose betrixaban
to prevent 1 fatal or irreversible event.
Findings from the ADOPT (Apixaban Dosing to Optimize
Protection from Thrombosis) trial5 did not demonstrate
benefit but showed an increase in major bleeding (0.47%
versus 0.19%) when comparing apixaban versus enoxaparin,
making it impossible to demonstrate a net clinical benefit.
Although results from the MAGELLAN (Venous Thromboem-
bolic Event [VTE] Prophylaxis in Medically Ill Patients) trial6
demonstrated a reduction in the primary end point, this was
offset by an increase in fatal bleeding (7 fatal bleeds versus 1
fatal bleed, P<0.034) and an increase in intracranial hemor-
rhage (2 versus 0, P<0.25), making it difficult to demonstrate
a favorable reduction in fatal or irreversible events. Neither
ADOPT nor MAGELLAN published analyses of fatal or
irreversible end points.
It is notable that death, MI, and stroke, a combined end
point often used in “arterial” cardiovascular trials, was
reduced in acutely ill medical patients treated with betrixaban,
a treatment, which was aimed at reducing “venous” throm-
boses events.
Limitations
The case report forms did not characterize whether the
recurrent MIs were ST-segment elevation myocardial infarc-
tions or non–ST-segment elevation myocardial infarctions,
and infarct size of the recurrent MIs was not quantitated. In
addition, adjudication was not performed to determine
whether there was a segmental versus subsegmental involve-
ment among patients with PE. Finally, this analysis did not use
weighted outcomes to incorporate physician and patient
preference regarding their perceived import regarding the
outcomes.
Conclusions
Among hospitalized medically ill patients, extended-duration
betrixaban demonstrates a favorable net clinical outcome and
is associated with an 30% reduction in fatal or irreversible
ischemic or bleeding events compared with standard-duration
enoxaparin followed by placebo. A total of 65 patients would
require treatment with betrixaban to prevent 1 fatal or
irreversible event versus enoxaparin.
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Table S1. Sensitivity Analysis for Composite of Fatal or Irreversible Events Using Cochran-Mantel-Haenszel Test 
 
  Through Visit 3 or Day 42 Through day 77 
  
Betrixaban  
no./total no. (%) 
Enoxaparin 
no./total no. (%) P-Value* 
Betrixaban  
no./total no. (%) 
Enoxaparin 
no./total no. (%) P-Value* 
Composite             
       Cohort 1 82/2314 (3.5) 111/2313 (4.8) 0.028 101/2314 (4.4) 145/2313 (6.3) 0.003 
       Cohort 2 105/3407 (3.1) 139/3391 (4.1) 0.017 133/3407 (3.9) 180/3391 (5.3) 0.004 
       All Randomized  
       Patients 109/3759 (2.9) 153/3754 (4.1) 0.003 137/3759 (3.6) 194/3754 (5.2) 0.001 
              
Composite - 80mg             
       Cohort 1 56/1828 (3.1) 86/1826 (4.7) 0.009 70/1828 (3.8) 112/1826 (6.1) 0.001 
       Cohort 2 73/2720 (2.7) 109/2718 (4.0) 0.005 95/2720 (3.5) 140/2718 (5.2) 0.002 
       All Randomized  
       Patients 74/118 (2.5) 118/2990 (4.0) 0.001 96/2987 (3.2) 149/2990 (5.0) 0.001 
              
Composite - 40mg             
       Cohort 1 25/484 (5.2) 24/483 (5.0) 0.940 30/484 (6.2) 32/483 (6.6) 0.679 
       Cohort 2 30/683 (4.4) 29/668 (4.3) 0.987 36/683 (5.3) 39/668 (5.8) 0.590 
       All Randomized  
       Patients 30/730 (4.1) 31/725 (4.3) 0.893 36/730 (4.9) 41/725 (5.7) 0.512 
              
Composite - Excluding Non-Fatal PE           
       Cohort 1 78/2314 (3.4) 96/2313 (4.2) 0.151 97/2314 (4.2) 130/2313 (5.6) 0.019 
       Cohort 2 98/3407 (2.9) 124/3391 (3.7) 0.055 126/3407 (3.7) 164/3391 (4.8) 0.016 
       All Randomized  
       Patients 101/3759 (2.7) 136/3754 (3.6) 0.014 129/3759 (3.4) 176/3754 (4.7) 0.004 
              
Composite - Excluding Non-Fatal PE + MI     








       Cohort 2 89/3407 (2.6) 115/3391 (3.4) 0.048 120/3407 (3.5) 152/3391 (4.5) 0.037 
       All Randomized  
       Patients 92/3759 (2.5) 127/3754 (3.4) 0.012 123/3759 (3.3) 164/3754 (4.4) 0.010 
 
*For cohort 1, treatment and the composite endpoint were stratified by dosing criteria (creatinine clearance ≥15ml and <30 ml/min, receipt of a concomitant pgp inhibitor with severe renal insufficiency, 








Table S2. Sensitivity Analysis for Composite of Fatal or Irreversible Events Using All-Cause Death  
 
 
  Through Visit 3 or Day 42 Through day 77 
  
Betrixaban  
no./total no. (%) 
Enoxaparin 
no./total no. (%) 
Hazard Ratio 
(95% CI) P-Value 
Betrixaban  
no./total no. (%) 
Enoxaparin 
no./total no. (%) 
Hazard Ratio 
(95% CI) P-Value 
Composite* 
       Cohort 1 128/2314 (5.5) 149/2313 (6.4) 0.86 (0.68, 1.08) 0.196 171/2314 (7.4) 202/2313 (8.7) 0.85 (0.69, 1.04) 0.105 
       Cohort 2 169/3407 (5.0) 189/3391 (5.6) 0.89 (0.72, 1.09) 0.257 227/3407 (6.7) 255/3391 (7.5) 0.89 (0.74, 1.06) 0.182 
       All Randomized Patients 175/3759 (4.7) 208/3754 (5.5) 0.84 (0.69, 1.02) 0.084 235/3759 (6.3) 277/3754 (7.4) 0.84 (0.71, 1.01) 0.057 
 
 









Table S3. Composite of Fatal and Irreversible Events – Full Dose (80mg) 
 
 Through Visit 3 or day 42  Through day 77 
Outcome* 
Betrixaban 
no./total no. (%) 
Enoxaparin‡ 
no./total no. (%) 
Betrixaban 
no./total no. (%) 
Enoxaparin‡ 
no./total no. (%) 
Cohort 1 
Composite - n/N (%) 56/1828 (3.1) 86/1826 (4.7) 70/1828 (3.8) 112/1826 (6.1) 
Ischemic Events – n     
      Ischemic cardiopulmonary death† 47 54 59 73 
      Nonfatal ischemic stroke 4 10 5 12 
      Myocardial infarction 9 11 10 15 
      Nonfatal pulmonary embolism 2 13 2 16 
Bleed Events – n     
      Fatal Bleed 0 1 0 1 
      Intracranial Hemorrhage 0 3 0 4 
  
    Cohort 2 
Composite 73/2720 (2.7) 109/2718 (4.0) 95/2720 (3.5) 140/2718 (5.2) 
Ischemic Events     
      Ischemic cardiopulmonary death 57 69 74 90 
      Nonfatal ischemic stroke 7 13 8 17 
      Myocardial infarction 12 13 13 17 
      Nonfatal pulmonary embolism 4 14 4 18 
Bleed Events     
      Fatal Bleed 0 1 0 1 
      Intracranial Hemorrhage 1 5 1 6 
  
    All Randomized Patients 
Composite 74/2987 (2.5) 118/2990 (4.0) 96/2987 (3.2) 149/2990 (5.0) 
Ischemic Events     
      Ischemic cardiopulmonary death 58 77 75 98 
      Nonfatal ischemic stroke 7 14 8 18 
      Myocardial infarction 12 14 13 18 
      Nonfatal pulmonary embolism 4 14 4 18 
Bleed Events     
      Fatal Bleed 0 1 0 1 
      Intracranial Hemorrhage 1 5 1 6 
* Data for safety outcomes were evaluated through visit 3 or day 42. The breakdown of events adds up to more than composite events because 
composite only includes first event patient experienced. Cohort 1 and Cohort 2 analyses use mITT population.  
†Includes fatal PE/VTE - confirmed, fatal PE/VTE - possible, fatal PE/VTE - probable, arrhythmic event, heart failure, fatal ischemic stroke, fatal 
myocardial infarction, sudden death of unknown cause       










Table S4. Composite of Fatal and Irreversible Events – Reduced Dose (40mg) 
 
 Through Visit 3 or day 42  Through day 77 
Outcome* 
Betrixaban 
no./total no. (%) 
Enoxaparin‡ 
no./total no. (%) 
Betrixaban 
no./total no. (%) 
Enoxaparin‡ 
no./total no. (%) 
Cohort 1 
Composite - n/N (%) 25/484 (5.2) 24/483 (5.0) 30/484 (6.2) 32/483 (6.6) 
Ischemic Events – n     
      Ischemic cardiopulmonary death† 20 20 24 26 
      Nonfatal ischemic stroke 1 1 2 2 
      Myocardial infarction 2 1 2 3 
      Nonfatal pulmonary embolism 3 3 3 3 
Bleed Events – n     
      Fatal Bleed 0 0 0 0 
      Intracranial Hemorrhage 0 0 0 0 
  
    Cohort 2 
Composite 30/683 (4.4) 29/668 (4.3) 36/683 (5.3) 39/668 (5.8) 
Ischemic Events     
      Ischemic cardiopulmonary death 22 23 27 30 
      Nonfatal ischemic stroke 1 2 2 3 
      Myocardial infarction 2 2 2 5 
      Nonfatal pulmonary embolism 4 3 4 3 
Bleed Events     
      Fatal Bleed 1 0 1 0 
      Intracranial Hemorrhage 0 0 0 0 
  
    All Randomized Patients 
Composite 30/730 (4.1) 31/725 (4.3) 36/730 (4.9) 41/725 (5.7) 
Ischemic Events     
      Ischemic cardiopulmonary death 22 25 27 32 
      Nonfatal ischemic stroke 1 2 2 3 
      Myocardial infarction 2 2 2 5 
      Nonfatal pulmonary embolism 4 3 4 3 
Bleed Events     
      Fatal Bleed 1 0 1 0 
      Intracranial Hemorrhage 0 0 0 0 
* Data for safety outcomes were evaluated through visit 3 or day 42. The breakdown of events adds up to more than composite events because 
composite only includes first event patient experienced. Cohort 1 and Cohort 2 analyses use mITT population.  
†Includes fatal PE/VTE - confirmed, fatal PE/VTE - possible, fatal PE/VTE - probable, arrhythmic event, heart failure, fatal ischemic stroke, fatal 
myocardial infarction, sudden death of unknown cause     






































*End of Trial defined as final follow-up visit (30 + 5 days after Visit 3) 

















*End of Trial defined as final follow-up visit (30 + 5 days after Visit 3) 




























*End of Trial defined as final follow-up visit (30 + 5 days after Visit 3) 






















Figure S6. Time-to-First Fatal or Irreversible Event in the All Randomized Population – 






*End of Trial defined as final follow-up visit (30 + 5 days after Visit 3) 





























*End of Trial defined as final follow-up visit (30 + 5 days after Visit 3) 









Appendix: APEX Investigators (No. of patients enrolled in each country, No. of sites):   
 
Argentina (215 patients, 7 sites): F. Bello, A.E. Ferrari, H. Jure, S. Macin, M. Oliva, M. Parody, C. Poy; 
Australia (20 patients, 5 sites): R. Baker, D. Colquhoun, P. Coughlin, S. Finfer, G. Hammerschlag , A. 
Rubinfeld; Austria (15 patients, 5 sites): K. Huber, J. König, R. Mathies, E. Pilger, H. Schoenerr; 
Belarus (69 patients, 7 sites): I. Adzerikho, V. Koryk, E. Mikhailova, N. Mitkovskaya, S. Pimanov, L. 
Polonetsy, N. Soroka; Belgium (15 patients, 5 sites): D. Blockmans, M. Delforge, A. Dive, F. Lienart, S. 
Motte; Brazil (57 patients, 8 sites): J. Annichino Bizzacchi, E. Fiss, A. Freire, E, Manenti, E. 
Ramacciotti, S. Raymuno, A. Rocha, J.F. Saraiva; Bulgaria (431 patients, 15 sites): B. Dimov, M. 
Grigorov, R. Kalpachki, Z. Kamenova, M. Kostadinova, M. Milanova, V. Mincheva, G. Pencheva, D. 
Raev, N. Runev, N. Stoeva, M. Stoyanov, S. Syulemzova, G. Todorov, M. Tokmakova; Canada (51 
patients, 7 sites): A. Dhar, J. Douketis, S. Kahn, G. Le Gal, M. Pearce, S. Provencher, S. Verreault; 
Chile (44 patients, 4 sites): M. Arias Alarcon, C. Olivares Cañon, M. Opazo Lazcano, S. Potthoff 
Cardenas; Croatia (92 patients, 11 sites): S. Butkovic-Soldo, S. Car, N. Ciglenecki, I. Francetic, M. 
Jakopovic, H. Kalinic-Grgorinic, A. Knezevic, B. Malojcic, S. Marusic, J. Sikic Vagic, V. Skerk; Czech 
Republic (237 patients, 22 sites): O. Cermak, P. Červinka,  J. Chlumsky, J. Chochola, V. Cizek, M. 
Dunaj, J. Dusek, L. Francek, J. Havelka, M. Herold, R. Holaj, I. Horny, J. Hubac, P. Jajtner, P. Kolman, 
P. Lang, O. Mayer, J. Mikulova, I Podpera, P.Reiterer, R. Spacek, J. Vejvoda, M. Vyhnanek; Denmark 
(12 patients, 5 sites): H. Christensen, M. Lassen, M. Storgaard, C. Tuxen, S. Urhammer; Estonia (205 
patients, 3 sites): M. Lember, T. Marandi, T. Uuetoa; Finland (26 patients, 7 sites): J. Airaksinen, J. 
Honkaniemi, R. Kaaja, R. Lassila, J. Saarinen, T. Tatlisumak, S. Vikman; France (293 patients, 25 
sites): B. Agraou, S. Aquilanti, A. Belhassane, D. Brisot, G. De Geeter, P. Debourdeau, E. Decoulx, D. El 
Kouri, N. Falvo, C. Grange, P. Lacroix, E. Messas, P. Mismetti, K. Montaclair, D. Mottier, N. Paleiron, 
L. Payot, G. Pernod, P. Pottier, A. Proust, I. Quere, P-M. Roy, J. Schmidt, G. Simoneau;  Georgia (260 
patients, 8 sites): I. Datikashvili-David, G. Khabeishvili, I. Khintibidze, B. Kobulia, I. Megreladze, Z. 
Pagava, K. Paposhvili, T. Shaburishvili; Germany (196 patients, 20 sites): B. Amann, J. Berrouschot, J. 
Beyer-Westendorf, E. Blessing, M. Bott, T. Dengler, C. Diehm, R. Dziewas, S. Genth-Zotz, F. Hamann, 
T. Horacek, S. Klimpe, R. Kröning, H. Lapp, H. Lawall, M. Licka, T. Rizos, S. Schellong, J. Schmidt-
Lucke, C. Singer, C. Tiefenbacher, R. Veltkamp, C. Weimar, U. Zeymer; Hungary (252 patients, 20 
sites): B. Alkonyi, J. Faluközy, L. Futo, A. Katona, R. Kirschner, P. Kristóf, F. Lakatos, Z. Laszlo, G. 
Lupkovics, B. Merkely, C. Nagy András, L. Németh, A. Papp, P. Soltesz, Z. Sudár, G. Szabo, N. Szegedi, 
G. Tímár, J. Valcó, A. Vertes; Israel (99 patients, 8 sites): S. Efrati, M. Elias, A. Gafter, T. Hayek, O. 
Hussein, M. Lishner, G. Lugassy, D. Zeltser; Italy (261 patients, 19 sites): W. Ageno, I. Cerveri, A. 
D’Angelo, A. De Pellegrin, D. Imberti, R. Landolfi, G. Lembo, C. Lodigiani, M. Luisetti, M. Moia, M. 
Molteni, N. Mumoli, S. Novo, F. Orlandini, R. Parisi, A. Pizzini, F. Pomero, A. Salvi, A. Schenone, A. 
Visonà; Latvia (319 patients, 5 sites): D. Krievins, V. Martinova, N. Pontaga, V. Rozitis, I. Stukena; 
Lithuania (470 patients, 12 sites): B. Alekniene, A. Bagdonas, V. Basijokiene, Z. Butkiene, V. 
Griskeviciene, A. Naudziunas, R. Norvaisiene, R. Norviliene, R. Petrauskiene, R. Poskiene, D. 
Susinskiene, A. Valavicius; Peru (152 patients, 7 sites): R. Castillo Leon, R. Cotrina Pereyra, L. 
Farjardo Karlo, M. Horna, J. Lema Osores, M. Salas, L. Toche Yañez; Poland (369 patients, 16 sites): 
W. Fryze, Z. Gaciong, J. Gniot, D. Gorecka, P. Gruenpeter, P. Grzelakowski, D. Jastrzebski, L. 
Kucharski, E. Mirek-Bryniarska, G. Pulkowski, B. Sobkowicz, P. Sulik, W. Tomkowski, L. Walasek, K. 
Waldemar, K. Wrzesinski; Romania (170 patients, 10 sites): Z.E. Balogh, M. Bojinca, I. Marin, S. Mot, 
R. Musetescu, C. Podoleanu, M. Popescu, S. Stamate, G. Stanciulescu, L. Vida-Simiti; Russia (971 
patients, 37 sites): A. Abashev, D. Andreev, K. Apartsin, M. Arkhipov, O. Averkov, O. Barbarash, G. 
Belskaya, E. Bogdanov, S. Boldueva, Z. Chefranova, Y. Dovgalevskiy, O. Ershova, B. Goloshchekin, N. 
Khachatryan, E. Khurs, G. Klein, Z. Kobalava, E. Kosmacheva, V. Kostenko, A. Malygin, T. 
Martynenko, V. Martynenko, N. Maslova, V. Mordovin, K. Nikolaev, R. Nilk, E. Panchenko, D. Popov, 








Solovyov, E. Vishneva, A. Vishnevskiy; Serbia (115 patients, 5 sites): S. Apostolovic, V. Celic, S. Ilic, 
A. Kovacevic-Kuzmanovic, V. Miloradovic; Singapore (1 patient, 1 site): R.S. Tan; Slovak Republic 
(105 patients, 11 sites): S. Bodikova, A. Cervenakova, M. Dvorak, L. Gaspar, O. Herman, A. Hrubon, 
M. Kokles, G. Krastev, J. Payer, D. Prokop, M. Spisakova; South Africa (91 patients, 7 sites): D. Adler, 
M. Basson, J. Breedt, j. Engelbrecht, B. Jacobson, I. Mitha, C. Van Dyk; Spain (412 patients, 18 sites): 
L.A. Alvarez Sala, C. Barbagelata López, J. Bisbe, A. Castro Guardiola, J.M. Cepeda, F. Cereto, E. Diaz 
Santos, R. Ferrer, J. Gomez Cerezo, J.R. Gonzales-Porras, J.Grandes, D. Jiménez, I. Martín Loeches, L. 
Mellibovsky, C. Richart, A. Riera, J. Trujillo, J.A. Vargas Nunez, J. Villalta; Turkey (54 patients, 12 
sites): O. Akgul, S. Guneri, K. Kilichesmez, C. Kırma, H. Kutluk, B. Nazliel, G. Okumus, G. Ongen, K. 
Tigen, M. Topcuoglu, E. Tuncay; Ukraine (886 patients, 31 sites): O. Abrahamovych, V. Batushkin, J. 
Brozhyk, I. Burmak, O. Godlevska, A. Goloborodko, B. Goloborodko, Y. Goncharova, V. Gryb, O. 
Karpenko, M. Kopytsya, V. Koshlia, O. Krakhmalova, I. Kyrychenko, O. Legkonogov, Y. Malynovsky, 
V. Maslovaskyi, V. Nikonov, O. Parkhomenko, M. Perepeliuk, D. Reshotko, L. Rudenko, T. 
Ryabichenko, I. Svyridova, Y. Svyshchenko, V. Tseluyko, G. Ursol, I. Vakaliuk, I. Vishnivestsky, L. 
Voronkov, A. Yagensky; United Kingdom (22 patients, 5 sites): R. Body, D. Chandra,  M. Davis, P. 
Kesteven, P. MacCallum, C. McCollum, I. Natarajan; USA (527 patients, 68 sites): E. Almasri, M. 
Amin, C. Anderson, S. Baker, J. Barney, B. Barth A. Bastani, P. Bercz, M. Bidair, T. Carman, H. Chang, 
C. Clark, M. Concha, J. Cornell, R. Dhingra, A. Doshi, R. Ebrahimi,  B. Farley, G. Fermann, G. Foster, J. 
Fraiz, J. Fulmer, H. Gaggin, D. Goytia-Leos, B. Hahn, A. Haidar, A. Hamad, M. Hazelrigg, O. 
Ioachimescu, B. Johnson,  H. Kabler, C-K. Kao, M. Kazimir, F. Kouras, M. Kung, R. Lerner, J. Lopez, A. 
Macchiavelli, S. Mahal, B. Margolis, G. McLaren, T. Milling Jr., M. Mittal, V. Nadar, V. Ohaju, T. Ortel, 
J. Overcash, K. Parthiban, R. Pearl, L. Pineda, R. Pratt, J. Pullman, O. Quintana, R. Rajan, P. Rastogi, C. 
Rees, W. Rodriguez, F. Saba, N. Shammas, S. Sharma. S. Sokol, S. Stoltz, D. Subich,  M. Tuck, J. 
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